ResearcherTongji UniversityNo recent work listed
Baomin Shi
Matched on ORCID iD 0000-0001-8791-569X; OpenAlex author ID A5082163270. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 7
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper
Papers 5
- Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting mi… Last author DOI 10.1016/j.drup.2023.100960↗
- TRPM2 promotes pancreatic cancer by PKC/MAPK pathway. Last author DOI 10.1038/s41419-021-03856-9↗
- Asymptomatic gastric adenomyoma and heterotopic pancreas in a patient with pancreatic cancer: A case report and review of the literature. Last author DOI 10.12998/wjcc.v9.i27.8147↗
- TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma. Last author DOI 10.3892/mmr.2018.8816↗
- Functional modules analysis based on coexpression network in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12253-013-9694-1↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Rui Lin · 3 shared papers, 2018–2023 · strength 0.39
- Paper Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secr… DOI 10.1016/j.drup.2023.100960↗
- Paper TRPM2 promotes pancreatic cancer by PKC/MAPK pathway. DOI 10.1038/s41419-021-03856-9↗
- Paper TRPM2 promotes the proliferation and invasion of pancreatic ductal adenocarcinoma. DOI 10.3892/mmr.2018.8816↗
- Yufeng Wang · 2 shared papers, 2018–2023 · strength 0.25
- Kun Li · 1 shared paper, 2021 · strength 0.19
- Ran Qi · 1 shared paper, 2023 · strength 0.16
- Kaixing Ai · 1 shared paper, 2021 · strength 0.14
- Pengfei Liu · 1 shared paper, 2014 · strength 0.05
- Yan Li · 1 shared paper, 2014 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.